MP4, a new nonvasoactive PEG‐Hb conjugate

BACKGROUND: Vasoconstriction has been an obstacle to clinical development of Hb‐based O2 carriers. It is proposed that this limitation can be overcome by increasing molecular size and oxygen affinity.

[1]  R. Shorr,et al.  The impact of polyethylene glycol conjugation on bovine hemoglobin's circulatory half-life and renal effects in a rabbit top-loaded transfusion model. , 2008, Artificial organs.

[2]  R. Koehler,et al.  Vascular response to infusions of a nonextravasating hemoglobin polymer. , 2002, Journal of applied physiology.

[3]  A. Popel,et al.  Model of nitric oxide diffusion in an arteriole: impact of hemoglobin-based blood substitutes. , 2002, American journal of physiology. Heart and circulatory physiology.

[4]  K. Vandegriff,et al.  The role of facilitated diffusion in oxygen transport by cell-free hemoglobins: implications for the design of hemoglobin-based oxygen carriers. , 2001, Biophysical chemistry.

[5]  K. Vandegriff Haemoglobin-based oxygen carriers , 2000, Expert opinion on investigational drugs.

[6]  S. Takeoka,et al.  Molecular dimensions of Hb-based O(2) carriers determine constriction of resistance arteries and hypertension. , 2000, American journal of physiology. Heart and circulatory physiology.

[7]  R. Winslow αα–Crosslinked Hemoglobin: Was Failure Predicted by Preclinical Testing? , 2000, Vox Sanguinis.

[8]  R. Winslow αα‐Crosslinked Hemoglobin: Was Failure Predicted by Preclinical Testing? , 2000, Vox sanguinis.

[9]  M. Goldman Diaspirin cross-linked hemoglobin (DCLHb) in the treatment of severe traumatic hemorrhagic shock: A randomized controlled efficacy trial , 2000 .

[10]  D. Gens,et al.  Diaspirin Cross-Linked Hemoglobin (DCLHb) in the Treatment of Severe Traumatic Hemorrhagic Shock: A Randomized Controlled Efficacy Trial , 1999 .

[11]  M. Kaste,et al.  Controlled safety study of a hemoglobin-based oxygen carrier, DCLHb, in acute ischemic stroke. , 1999, Stroke.

[12]  Hiromi Sakai,et al.  Plasma viscosity regulates capillary perfusion during extreme hemodilution in hamster skinfold model. , 1998, American journal of physiology. Heart and circulatory physiology.

[13]  K. Vandegriff,et al.  Vascular resistance and the efficacy of red cell substitutes in a rat hemorrhage model. , 1998, Journal of applied physiology.

[14]  J. Olson,et al.  Rate of reaction with nitric oxide determines the hypertensive effect of cell-free hemoglobin , 1998, Nature Biotechnology.

[15]  K. Vandegriff,et al.  Arterial Blood Pressure Responses to Cell-free Hemoglobin Solutions and the Reaction with Nitric Oxide* , 1998, The Journal of Biological Chemistry.

[16]  K. Vandegriff,et al.  Hemoglobin-oxygen equilibrium curves measured during enzymatic oxygen consumption. , 1998, Analytical biochemistry.

[17]  K. Vandegriff,et al.  Colloid osmotic properties of modified hemoglobins: chemically cross-linked versus polyethylene glycol surface-conjugated. , 1997, Biophysical chemistry.

[18]  F. Pieruzzi,et al.  Effects of polymerization on the hypertensive action of diaspirin cross-linked hemoglobin in rats. , 1997, The Journal of laboratory and clinical medicine.

[19]  K. Vandegriff,et al.  Blood volume and cardiac index in rats after exchange transfusion with hemoglobin-based oxygen carriers. , 1997, Journal of applied physiology.

[20]  R. Winslow,et al.  Microvascular and tissue oxygen distribution. , 1996, Cardiovascular research.

[21]  K. Vandegriff,et al.  Equilibrium oxygen binding to human hemoglobin cross-linked between the alpha chains by bis(3,5-dibromosalicyl) fumarate. , 1989, The Journal of biological chemistry.

[22]  S. Snell,et al.  A convenient spectroscopic method for the estimation of hemoglobin concentrations in cell-free solutions. , 1988, Journal of biochemical and biophysical methods.

[23]  P. Keipert,et al.  Cross-linked Stroma-free Polyhemoglobin as a Potential Blood Substitute , 1982, The International journal of artificial organs.

[24]  R. Tuma,et al.  Influence of oxygen on perfused capillary density and capillary red cell velocity in rabbit skeletal muscle. , 1980, Microvascular research.

[25]  J. Arnold,et al.  A clinical safety trial of stroma‐free hemoglobin , 1978, Clinical pharmacology and therapeutics.

[26]  R L Berger,et al.  Oxygen equilibrium curve of normal human blood and its evaluation by Adair's equation. , 1977, The Journal of biological chemistry.

[27]  V. E. Ayers,et al.  Determination of the reactive sulfhydryl groups in heme proteins with 4,4'-dipyridinedisulfide. , 1969, Analytical biochemistry.

[28]  R. Winslow New transfusion strategies: red cell substitutes. , 1999, Annual review of medicine.

[29]  A. Pope,et al.  Fluid Resuscitation: State of the Science for Treating Combat Casualties and Civilian Injuries , 1999 .

[30]  K. Vandegriff,et al.  Hemoglobin Oxygen Affinity and the Design of Red Cell Substitutes , 1997 .

[31]  K. Vandegriff,et al.  A Theoretical Analysis of Oxygen Transport: A New Strategy for the Design of Hemoglobin-Based Red Cell Substitutes , 1995 .

[32]  R. Winslow,et al.  Pilot-scale preparation of hemoglobin solutions. , 1994, Methods in enzymology.

[33]  C. Mackenzie Hemoglobin-based Red Cell Substitutes , 1993 .

[34]  Winslow Rm,et al.  The intravascular persistence of crosslinked human hemoglobin. , 1989 .

[35]  R. Winslow,et al.  The intravascular persistence of crosslinked human hemoglobin. , 1989, Progress in clinical and biological research.

[36]  T. Chang,et al.  Pyridoxylated-polyhemoglobin solution: a low viscosity oxygen-delivering blood replacement fluid with normal oncotic pressure and long-term storage feasibility. , 1988, Biomaterials, artificial cells, and artificial organs.

[37]  R. Benesch Preparation and properties of hemoglobin modified with derivatives of pyridoxal. , 1981, Methods in enzymology.

[38]  M. Perutz,et al.  Three dimensional fourier synthesis of horse deoxyhaemoglobin at 2.8 Angstrom units resolution. , 1970, Nature.

[39]  W. R. Amberson,et al.  Clinical experience with hemoglobin-saline solutions. , 1947, Year book - American Philosophical Society.